Sept. 12, 2025:
The Big Ten Cancer Research Consortium congratulates Greg Durm, MD, on receiving the 2025 Pat Loehrer Award for Exemplary Collaboration in Cancer Research.
The award was presented to Dr. Durm on Friday, September 12, during the 2025 Big Ten CRC Summit in Rosemont, Ill.
Created in 2021, the award is presented annually by the Big Ten CRC cancer center directors to an individual researcher who best demonstrates collaboration within the Big Ten CRC. It is named in honor of Patrick J. Loehrer, MD, founding visionary of the Big Ten CRC and Distinguished Professor, Joseph W. and Jackie J. Cusick Professor of Oncology, Professor of Medicine, and Program Leader of Global Oncology at Indiana University Melvin and Bren Simon Comprehensive Cancer Center. Past recipients include Dr. Loehrer (inaugural recipient), George Weiner, MD, of the Holden Comprehensive Cancer Center at the University of Iowa, and Kari Wisinski, MD, of the UW Carbone Cancer Center.
Dr. Durm is an associate professor of clinical medicine in the Division of Hematology/Oncology and an associate professor of clinical otolaryngology at the Indiana University School of Medicine. He is also a full member of the Experimental and Developmental Therapeutics Program at the IU Melvin and Bren Simon Comprehensive Cancer Center.
Within the Big Ten CRC, Dr. Durm is a long-time member and current co-chair the Thoracic Clinical Trial Working Group and has led several successful consortium studies, including:
- BTCRC-LUN18-153: A randomized phase II trial of adjuvant pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1–4 cm. (NCT04317534)
- BTCRC-LUN16-081: Randomized phase II study of consolidation immunotherapy with nivolumab and ipilimumab or nivolumab alone following concurrent chemoradiotherapy for unresectable stage IIIA/IIIB non-small-cell lung cancer. (NCT03285321)
- BTCRC-LUN15-029: A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non-small cell lung cancer previously treated with a PD-1 or PD-L1 inhibitor. (NCT03083808)
The Big Ten CRC congratulates Dr. Durm on this well-deserved honor, and we look forward to his continued contributions to the consortium and the field of oncology.
About the Big Ten Cancer Research Consortium: The Big Ten Cancer Research Consortium was created in 2013 to transform the conduct of cancer research through collaborative clinical trials and observational studies that seek to improve the lives of cancer patients in the diverse communities we serve by leveraging the scientific and clinical expertise of Big Ten universities. The Big Ten Cancer Research Consortium creates a unique team research culture to drive science rapidly from ideas to treatment and prevention. Within this innovative environment, today’s research leaders collaborate with and mentor the research leaders of tomorrow. Since its founding, the Big Ten CRC has activated nearly 40 clinical trials across a wide range of cancer types, more than 1,000 participants have enrolled in Big Ten CRC studies, and more than 500 researchers have joined Big Ten CRC Clinical Trial Working Groups.
About the Big Ten Conference: The Big Ten Conference is an association of world-class universities whose member institutions share a common mission of research, graduate, professional and undergraduate teaching and public service. Founded in 1896, the Big Ten has sustained a comprehensive set of shared practices and policies that enforce the priority of academics in the lives of students competing in intercollegiate athletics and emphasize the values of integrity, fairness and competitiveness. The broad-based programs of the 18 Big Ten institutions provide direct financial support for more than 11,000 participation opportunities on 350 teams in 42 different sports. The Big Ten sponsors 28 official conference sports, 14 for men and 14 for women. For more information, visit www.bigten.org.
Subscribe to the Big Ten CRC Newsletter
X
Facebook
YouTube